LncRNA As a Prognostic Biomarker for Various Cancers: A Meta-analysis and Bioinformatics Analysis

Overview

Journal Front Genet

Date 2022 Sep 1

PMID 36046244

Authors

Yongfeng Wang

Xianglai Jiang

Dongzhi Zhang

Yuanbin Zhao

Xiaoyong Han

Lihui Zhu

Jingyao Ren

Yubin Liu

Jiarong You

Haolan Wang

Hui Cai

Affiliations

Soon will be listed here.

Abstract

Dual homeoboxes A pseudogene 8 () is a newly discovered long noncoding RNA that has been shown to function as an oncogene in a variety of human malignant cancers. By integrating available data, this meta-analysis sought to determine the relationship between clinical prognosis and expression levels in diverse malignancies. A systematic search was performed to identify eligible studies from several electronic databases from their inception to 25 October 2021. Pooled odds ratios and hazard ratios with 95% CI were used to estimate the association between expression and survival. For survival analysis, the Kaplan-Meier method and COX analysis were used. Furthermore, we utilized Spearman's correlation analysis to explore the correlation between and tumor mutational burden (TMB), microsatellite instability (MSI), the related genes of mismatch repair (MMR), DNA methyltransferases (DNMTs), and immune checkpoint biomarkers. Our findings indicated that overexpression of was related to poor overall survival (OS) (HR = 1.63, 95% CI, 1.49-1.77, < 0.001). In addition, elevated expression was closely related to poor OS in several cancers in the TCGA database. Moreover, expression has been associated with TMB, MSI, and MMR in a variety of malignancies. This study revealed that might serve as a prognostic biomarker and potential therapeutic target for cancer. It can be used to improve cancer diagnosis, discover potential treatment targets, and improve prognosis.

Citing Articles

Radiotherapy and breast cancer: finally, an lncRNA perspective on radiosensitivity and radioresistance.

Yazarlou F, Martinez I, Lipovich L Front Oncol. 2024; 14:1437542.

PMID: 39346726 PMC: 11427263. DOI: 10.3389/fonc.2024.1437542.

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study.

Fang W, Peng X, Zhou Q J Cardiothorac Surg. 2024; 19(1):478.

PMID: 39090722 PMC: 11295867. DOI: 10.1186/s13019-024-02975-6.

Ferroptosis is a protective factor for the prognosis of cancer patients: a systematic review and meta-analysis.

Li S, Tao K, Yun H, Yang J, Meng Y, Zhang F BMC Cancer. 2024; 24(1):604.

PMID: 38760742 PMC: 11102205. DOI: 10.1186/s12885-024-12369-5.

The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis).

Taghizadeh M, Jafari-Koshki T, Jafarlou V, Raeisi M, Alizadeh L, Roosta Y BMC Cancer. 2024; 24(1):484.

PMID: 38627675 PMC: 11022431. DOI: 10.1186/s12885-024-12180-2.

Combined glucocorticoids and cyclophosphamide in the treatment of Graves' ophthalmopathy: a systematic review and meta-analysis.

Xiang Q, Yang M, Luo W, Cao Y, Shuai S, Wei X BMC Endocr Disord. 2024; 24(1):12.

PMID: 38273269 PMC: 10811849. DOI: 10.1186/s12902-024-01545-0.

References

Chen M, Zheng Y, Xie J, Zhen E, Zhou X . Integrative profiling analysis identifies the oncogenic long noncoding RNA DUXAP8 in oral cancer. Anticancer Drugs. 2020; 31(8):792-798. DOI: 10.1097/CAD.0000000000000936. View

Yan P, Yao L, Li H, Zhang M, Xun Y, Li M . The methodological quality of robotic surgical meta-analyses needed to be improved: a cross-sectional study. J Clin Epidemiol. 2018; 109:20-29. DOI: 10.1016/j.jclinepi.2018.12.013. View

Chen X, Gao J, Liang N . DUXAP8 knockdown inhibits the development of melanoma by regulating the miR-3182/NUPR1 pathway. Oncol Lett. 2021; 22(1):495. PMC: 8108271. DOI: 10.3892/ol.2021.12756. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Chen L, Wu C, Wang H, Chen S, Ma D, Tao Y . Analysis of Long Noncoding RNAs in Aila-Induced Non-Small Cell Lung Cancer Inhibition. Front Oncol. 2021; 11:652567. PMC: 8255921. DOI: 10.3389/fonc.2021.652567. View

Arabpour M, Layeghi S, Tavakkoly Bazzaz J, Naghizadeh M, Majidzadeh-A K, Shakoori A . The potential roles of lncRNAs DUXAP8, LINC00963, and FOXD2-AS1 in luminal breast cancer based on expression analysis and bioinformatic approaches. Hum Cell. 2021; 34(4):1227-1243. DOI: 10.1007/s13577-021-00539-7. View

Ilie M, Beaulande M, Hamila M, Erb G, Hofman V, Hofman P . Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer. Lung Cancer. 2018; 124:90-94. DOI: 10.1016/j.lungcan.2018.07.037. View

Wang Y, Lin K, Xu T, Wang L, Fu L, Zhang G . Development and validation of prognostic model based on the analysis of autophagy-related genes in colon cancer. Aging (Albany NY). 2021; 13(14):19028-19047. PMC: 8351728. DOI: 10.18632/aging.203352. View

Liu Y, Zhang H, Wang H, Du J, Dong P, Liu M . Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4. Bioengineered. 2021; 12(1):496-506. PMC: 8291844. DOI: 10.1080/21655979.2021.1882134. View

10.

Qi P, Du X . The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2012; 26(2):155-65. DOI: 10.1038/modpathol.2012.160. View

11.

Yang T, Guo J, Li F, Xiu C, Wang H, Duan X . Long non‑coding RNA‑DUXAP8 regulates TOP2A in the growth and metastasis of osteosarcoma via microRNA‑635. Mol Med Rep. 2021; 24(1). PMC: 8134877. DOI: 10.3892/mmr.2021.12150. View

12.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

13.

He W, Yu Y, Huang W, Feng G, Li J . The Pseudogene DUXAP8 Promotes Colorectal Cancer Cell Proliferation, Invasion, and Migration by Inducing Epithelial-Mesenchymal Transition Through Interacting with EZH2 and H3K27me3. Onco Targets Ther. 2020; 13:11059-11070. PMC: 7605666. DOI: 10.2147/OTT.S235643. View

14.

Ma H, Xie M, Sun M, Chen T, Jin R, Ma T . The pseudogene derived long noncoding RNA DUXAP8 promotes gastric cancer cell proliferation and migration via epigenetically silencing PLEKHO1 expression. Oncotarget. 2017; 8(32):52211-52224. PMC: 5581023. DOI: 10.18632/oncotarget.11075. View

15.

Ma Z, Huang H, Xu Y, He X, Wang J, Hui B . Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors. Onco Targets Ther. 2017; 10:4711-4717. PMC: 5626378. DOI: 10.2147/OTT.S136915. View

16.

Liu Y, Zhang G, Chen H, Wang H . Silencing lncRNA DUXAP8 inhibits lung adenocarcinoma progression by targeting miR-26b-5p. Biosci Rep. 2020; 41(1). PMC: 7791543. DOI: 10.1042/BSR20200884. View

17.

Bahrami A, Aledavood A, Anvari K, Hassanian S, Maftouh M, Yaghobzade A . The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs. J Cell Physiol. 2017; 233(2):774-786. DOI: 10.1002/jcp.25813. View

18.

Chen M, Fan M, Yang J, Lang J . Identification of Potential Oncogenic Long Non-Coding RNA Set as a Biomarker Associated with Colon Cancer Prognosis. J Environ Pathol Toxicol Oncol. 2020; 39(1):39-49. DOI: 10.1615/JEnvironPatholToxicolOncol.2020032351. View

19.

Lin M, Hong Y, Zhang Y, Lin B, He X . Mechanism of lncRNA DUXAP8 in promoting proliferation of bladder cancer cells by regulating PTEN. Eur Rev Med Pharmacol Sci. 2018; 22(11):3370-3377. DOI: 10.26355/eurrev_201806_15158. View

20.

Nie L, Li C, Zhao T, Wang Y, Liu J . LncRNA double homeobox A pseudogene 8 (DUXAP8) facilitates the progression of neuroblastoma and activates Wnt/β-catenin pathway via microRNA-29/nucleolar protein 4 like (NOL4L) axis. Brain Res. 2020; 1746:146947. DOI: 10.1016/j.brainres.2020.146947. View